Drug intelligence / Profile preview

CDP571

Development stage: Discontinued
Lead developer: CellTech Group
Modality: IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CDP571 is a humanized monoclonal antibody that targets tumor necrosis factor alpha (TNF-α), a protein involved in systemic inflammation. It was developed for the treatment of inflammatory conditions, particularly Crohn's disease. Clinical trials showed modest effectiveness for short-term treatment of Crohn's disease, with better responses observed in patients with elevated baseline C-reactive protein levels.

Other names: Humicade

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on CDP571.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDP571.

Explore the full profile